UBQLN1: A GTP-Binding Protein and Its Role in Cell Signaling (G29979)

Target Name: UBQLN1

NCBI ID: G29979

UBQLN1

UBQLN1: A GTP-Binding Protein and Its Role in Cell Signaling

Ubiquilin 1 (UBQLN1) is a protein that is expressed in nearly all cell types, albeit at low concentrations. UBQLN1 is a GTP-binding protein that plays an important role in cell signaling. Mutations in UBQLN1 cause a variety of genetic diseases, including neurodegenerative diseases, cancer, and autoimmune diseases. Therefore, UBQLN1 has become a very attractive drug target.

Biological function and structure of UBQLN1

UBQLN1 is a 120kDa protein consisting of 957 amino acids. It has a GTP-binding domain located at the N-terminus of the protein. The GTP-binding domain of UBQLN1 includes a GTP-binding site and a GTPase active center. The GTPase active center is one of the most important domains in GTP-binding proteins. It is an important region for GTP binding and regulating protein phosphorylation.

UBQLN1 interaction

UBQLN1 is a GTP-binding protein that can bind to GTP and regulate protein phosphorylation. GTP is an important energy molecule and plays an important role as a signaling molecule in organisms. UBQLN1 binds to GTP through the GTPase active center and uses GTP phosphorylation to regulate protein function.

The role of UBQLN1 in the nervous system

UBQLN1 plays an important role in the nervous system. UBQLN1 is one of the major components of neuronal GABAergic neurons. GABA is an important neurotransmitter that can regulate the excitatory and inhibitory states of neurons. The GTPase active center of UBQLN1 can phosphorylate GABA synapses, thereby increasing the concentration of GABA and enhancing synaptic transmission between neurons.

The role of UBQLN1 in cancer

UBQLN1 plays an important role in various cancers. Studies have shown that variations in UBQLN1 are associated with the risk of various cancers. Variations in UBQLN1 can lead to tumor initiation, growth and metastasis. In addition, UBQLN1 is also associated with cancer progression and treatment response. Therefore, UBQLN1 is considered

Protein Name: Ubiquilin 1

Functions: Plays an important role in the regulation of different protein degradation mechanisms and pathways including ubiquitin-proteasome system (UPS), autophagy and endoplasmic reticulum-associated protein degradation (ERAD) pathway. Mediates the proteasomal targeting of misfolded or accumulated proteins for degradation by binding (via UBA domain) to their polyubiquitin chains and by interacting (via ubiquitin-like domain) with the subunits of the proteasome (PubMed:15147878). Plays a role in the ERAD pathway via its interaction with ER-localized proteins UBXN4, VCP and HERPUD1 and may form a link between the polyubiquitinated ERAD substrates and the proteasome (PubMed:19822669, PubMed:18307982). Involved in the regulation of macroautophagy and autophagosome formation; required for maturation of autophagy-related protein LC3 from the cytosolic form LC3-I to the membrane-bound form LC3-II and may assist in the maturation of autophagosomes to autolysosomes by mediating autophagosome-lysosome fusion (PubMed:19148225, PubMed:20529957, PubMed:23459205). Negatively regulates the TICAM1/TRIF-dependent toll-like receptor signaling pathway by decreasing the abundance of TICAM1 via the autophagic pathway (PubMed:21695056). Promotes the ubiquitination and lysosomal degradation of ORAI1, consequently down-regulating the ORAI1-mediated Ca2+ mobilization (PubMed:23307288). Suppresses the maturation and proteasomal degradation of amyloid beta A4 protein (A4) by stimulating the lysine 63 (K63)-linked polyubiquitination. Delays the maturation of A4 by sequestering it in the Golgi apparatus and preventing its transport to the cell surface for subsequent processing (By similarity). Ubiquitinates BCL2L10 and thereby stabilizes protein abundance (PubMed:22233804)

The "UBQLN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBQLN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets